SP
Sun Pharma Advanced Research Company Ltd (SPARC)
₹203.00
Mkt cap
₹6,681 Cr
P/E ratio
4.19
P/B
4.94
Div yield
0.00%
ROE
281.00%
ROCE
165.00%
EPS (TTM)
₹48.45
Book value
₹41
52W range
109–278
Sector
Healthcare
Price history
Previous close
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]
NSE SPARCBSE 532872
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−26.87% from high₹203
₹109+86.74% from low₹278
Current
₹203.00
Prev close
₹206.90
Day
−1.88%
Price performance
1D
−1.88%
1W
+3.06%
1M
−2.11%
3M
−1.42%
6M
+63.60%
1Y
+41.44%
YTD
+49.57%
Financials
Revenue, profit & margin
P/E ratio
4.2×
SPARC is 88% below the sector median of 35.1×
SPARC4.2×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 | |
| Expenses | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 | 74 | 65 | 80 | 74 | |
| Operating Profit | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 | -66 | -57 | 1,773 | -34 | |
| OPM % | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% | -838% | -673% | 96% | -86% | |
| Other Income | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 | |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | |
| Profit before tax | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | -21 | |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 | -21 | |
| EPS in Rs | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 | -2.34 | -2.48 | 54.26 | -0.65 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.73% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26 |
| Earnings day | −2.73% |
| +1 day | −3.73% |
| +5 days | −7.43% |
| +15 days | −6.51% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202665.68%Promoter
Promoters65.68%0.01
FIIs3.90%1.86
DIIs0.09%0.79
Public30.34%1.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SPARC | ₹205.87 | 4.19 | 6,681 | 0.00% | −21 | +59.68% | 40 | +314.11% | 164.99% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts23
TranscriptJan 2026PPTJan 2026TranscriptDec 2024PPTDec 2024TranscriptApr 2024RECApr 2024TranscriptJan 2024TranscriptJan 2024PPTJan 2024PPTJan 2024TranscriptNov 2023PPTNov 2023TranscriptOct 2022PPTOct 2022TranscriptDec 2021PPTDec 2021PPTDec 2021PPTDec 2021PPTSep 2020PPTSep 2019PPTSep 2018PPTSep 2018PPTAug 2016
Credit ratings5
Announcements5
Filing Of Application For Reclassification With Stock Exchanges 13 Aug - SPARC filed application for promoter-group reclassification to public under Regulation 31A on August 13, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 11 AugShareholder Meeting / Postal Ballot-Outcome of AGM 10 Aug - 21st AGM on Aug 10, 2026 approved all resolutions, including appointment of Anil Raghavan as MD & CEO.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 10 Aug - Q1 FY27 monitoring report for ₹599.98 crore warrants issue shows no deviation and full loan repayment use.Unaudited Financial Results For The Quarter Ended June 30, 2026 10 Aug - Board approved Q1 FY27 results on August 10, 2026 and promoter-group reclassification requests.